Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AgomAb Therapeutics NV - ADRs representing one common share. (NQ:AGMB)

8.307 -0.023 (-0.28%)
Delayed Quote Updated: 11:13 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about AgomAb Therapeutics NV - ADRs representing one common share.

News headline image
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab to Participate in Upcoming Investor Conferences
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Announces Results of Annual General Meeting
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab to Participate in Upcoming Conferences
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
From AgomAb Therapeutics NV
Via GlobeNewswire
News headline image
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
From AgomAb Therapeutics N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.